Abstract 349P
Background
Indolent lymphomas, a heterogeneous group of non-Hodgkin lymphomas, exhibit a slow-growing nature and pose distinct clinical challenges due to their potential for relapse and transformation. While standard therapies have demonstrated efficacy in controlling disease progression, efforts to enhance treatment outcomes have led to investigations into combination regimens. Lenalidomide, an immunomodulatory agent with antiangiogenic and antitumor properties, has shown promise in various hematological malignancies. This meta-analysis aim to assess the impact of adding lenalidomide to standard therapy on overall survival (OS) and progression-free survival (PFS) in patients with indolent lymphoma.
Methods
A comprehensive search strategy was employed to identify relevant studies from electronic databases (PubMed, Embase, Web of Science) up to August 2023. Inclusion criteria encompassed randomized controlled trials (RCTs) that compared lenalidomide + standard therapy versus standard therapy alone in patients with indolent lymphoma. Pooled hazard ratios (HRs) for OS and PFS were calculated using random-effects models. Heterogeneity of the pooled analysis was measured by the chi-squared test and I2 statistic. All statistical analyses were conducted using RevMan software (version 5.4; Cochrane Collaboration, London, UK).
Results
The initial search yielded 573 articles, of which 4 randomized controlled trials (RCTs) met the eligibility criteria for inclusion in the meta-analysis. The combined data indicated that there was no statistically significant difference in OS (HR: 0.90; 95% CI: 0.59-1.38; p = 0.63; I2 = 24%) and PFS (HR: 0.76; 95% CI: 0.50-1.50; p = 0.20; I2 = 88%) between patients treated with lenalidomide + standard therapy and those receiving standard therapy alone for indolent lymphoma. Moreover, the use of lenalidomide was not significantly associated with neutropenia (OR: 2.76; 95% CI: 0.72-10.50; p = 0.14; I2 = 95%).
Conclusions
Incorporation of lenalidomide into standard therapy does not yield benefits in both OS and PFS. Due to heterogeneity in PFS and neutropenia pooled analysis, further trials are needed to confirm the results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract